Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review.

CONCLUSION: Denosumab can be used both as a first-line agent and an alternative to bisphosphonate in the treatment of postmenopausal osteoporosis. There is currently insufficient data to show that denosumab is not inferior to bisphosphonates in fracture prevention. PMID: 30854568 [PubMed - as supplied by publisher]
Source: Singapore Medical Journal - Category: General Medicine Authors: Tags: Singapore Med J Source Type: research